Alnylam Pharmaceuticals Inc (ALNY.OQ)
ALNY.OQ on NASDAQ Stock Exchange Global Select Market
94.51USD
8:07pm BST
94.51USD
8:07pm BST
Change (% chg)
$1.56 (+1.68%)
$1.56 (+1.68%)
Prev Close
$92.95
$92.95
Open
$93.18
$93.18
Day's High
$95.23
$95.23
Day's Low
$91.98
$91.98
Volume
161,797
161,797
Avg. Vol
283,669
283,669
52-wk High
$153.80
$153.80
52-wk Low
$70.78
$70.78
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 29.91 | -1.627 |
| Mar '18 | 21.90 | -1.420 | |
| FY 2017 | Dec '17 | 37.92 | -1.479 |
| Sep '17 | 17.10 | -1.339 | |
| Jun '17 | 15.93 | -1.344 | |
| Mar '17 | 18.96 | -1.247 | |
| FY 2016 | Dec '16 | 17.45 | -1.316 |
| Sep '16 | 13.65 | -1.214 | |
| Jun '16 | 8.71 | -1.054 | |
| Mar '16 | 7.34 | -1.208 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 12 | 24.99 | 53.80 | 7.00 | 39.98 |
| Quarter Ending Dec-18 | 12 | 31.93 | 68.41 | 7.97 | 67.92 |
| Year Ending Dec-18 | 16 | 108.52 | 160.80 | 68.00 | 120.30 |
| Year Ending Dec-19 | 17 | 232.01 | 518.29 | 97.27 | 316.09 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 12 | -1.98 | -1.80 | -2.30 | -1.38 |
| Quarter Ending Dec-18 | 12 | -2.09 | -1.68 | -2.72 | -1.20 |
| Year Ending Dec-18 | 14 | -7.12 | -6.51 | -7.70 | -5.31 |
| Year Ending Dec-19 | 15 | -7.16 | -5.66 | -9.65 | -3.60 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 85.68 | 32.76 | |
| P/E High - Last 5 Yrs. | -- | 300.64 | 45.44 | |
| P/E Low - Last 5 Yrs. | -- | 92.08 | 24.26 | |
| Beta | 2.97 | 0.93 | 0.89 | |
| Price to Sales (TTM) | 170.48 | 114.98 | 5.75 | |
| Price to Book (MRQ) | 10.02 | 15.51 | 5.47 | |
| Price to Tangible Book (MRQ) | 10.02 | 14.52 | 7.04 | |
| Price to Cash Flow (TTM) | -- | 72.88 | 23.29 | |
| % Owned Institutions | 96.38 | 14.70 | 2.21 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.36 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.26 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 1.72 | 5.22 | |
| Payout Ratio(TTM) | -- | 16.50 | 43.78 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 82.94 | 411.54 | 8.01 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 120.51 | 80.50 | 5.64 | |
| Sales - 5 Yr. Growth Rate | -10.64 | 32.27 | 10.18 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -27.58 | 29.15 | 20.60 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -20.86 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 39.84 | 10.66 | |
| Capital Spending - 5 Yr. Growth Rate | 118.68 | 40.43 | 15.34 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.91 | 2.22 |
| Current Ratio (MRQ) | 8.84 | 5.53 | 3.03 |
| LT Debt to Equity (MRQ) | 13.36 | 35.26 | 12.51 |
| Total Debt to Equity (MRQ) | 13.36 | 37.08 | 16.85 |
| Interest Coverage (TTM) | -- | -102.44 | 32.63 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 39.17 | 54.37 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.57 | 52.17 | |
| EBITD Margin (TTM) | -661.41 | -- | -- | |
| EBITD - 5 Yr. Avg | -480.35 | -603.21 | 10.65 | |
| Operating Margin (TTM) | -680.48 | -759.76 | 4.32 | |
| Operating Margin - 5 Yr. Avg. | -533.41 | -625.13 | 6.06 | |
| Pre-Tax Margin (TTM) | -670.81 | -733.60 | 5.18 | |
| Pre-Tax Margin - 5 Yr. Avg. | -518.10 | -628.46 | 6.49 | |
| Net Profit Margin (TTM) | -670.81 | -734.98 | 1.48 | |
| Net Profit Margin - 5 Yr. Avg. | -496.94 | -631.51 | 2.77 | |
| Effective Tax Rate (TTM) | -- | 23.33 | 23.11 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.66 | 23.97 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 128,399 | 23,229,989 | 860,364,355 | |
| Net Income/Employee (TTM) | -861,313 | 3,144,143 | 101,205,920 | |
| Receivable Turnover (TTM) | 5.30 | 20.89 | 5.87 | |
| Inventory Turnover (TTM) | -- | 2.46 | 3.41 | |
| Asset Turnover (TTM) | 0.05 | 0.41 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -31.44 | -0.16 | 11.13 | |
| Return on Assets - 5 Yr. Avg. | -31.82 | 3.50 | 12.40 | |
| Return on Investment (TTM) | -33.58 | 1.78 | 14.61 | |
| Return on Investment - 5 Yr. Avg. | -35.07 | 2.55 | 16.13 | |
| Return on Equity (TTM) | -39.86 | 3.28 | 16.33 | |
| Return on Equity - 5 Yr. Avg. | -40.19 | 3.42 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 14.75 | -0.01 | -10.64 |
| EPS (TTM) % | -38.73 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Alnylam Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 66.44 | 60.70 | 99 | 53 |
| 13 Week | 45.87 | 38.77 | 99 | 66 |
| 26 Week | 152.83 | 133.61 | 99 | 80 |
| 52 Week | 238.72 | 187.09 | 99 | 50 |
| YTD | 227.59 | 187.69 | 99 | 61 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UPDATE 1-Alnylam's gene silencing drug wins FDA approval
- Alnylam's gene silencing drug wins FDA approval
- BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics
- BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41
- BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran
Institutional Holders
| % Shares Owned: | 93.26% |
| # of Holders: | 451 |
| Total Shares Held: | 93,883,090 |
| 3 Mo. Net Change: | -233,681 |
| # New Positions: | 62 |
| # Closed Positions: | 45 |
| # Increased Positions: | 229 |
| # Reduced Positions: | 150 |
| # Net Buyers: | 79 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.